CUDC-101

Bezeichnung:CUDC-101

CAS-Nr1012054-59-9

Englisch Name:CUDC-101

CBNumberCB12500941

SummenformelC24H26N4O4

Molgewicht434.49

MOL-Datei1012054-59-9.mol

CUDC-101 physikalisch-chemischer Eigenschaften

Schmelzpunkt	174-177℃
Dichte	1.28
storage temp.	-20°C
Löslichkeit	DMSO: soluble
pka	9.47±0.20(Predicted)
Aggregatzustand	solid
Farbe	White or off-white
Stabilität	Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
InChIKey	PLIVFNIUGLLCEK-UHFFFAOYSA-N

Sicherheit

WGK Germany

Gefahreninformationscode (GHS)

CUDC-101 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
CUDC-101 (1012054-59-9) is a novel hybrid dual-acting HDAC and receptor tyrosine kinase inhibitor. It is a potent HDAC inhibitor which also inhibits EGFR and HER2,? IC50?= 4.4, 2.4 and 15.7 nM respectively.1?It not only blocks EGFR and HER2 but also attenuates multiple compensatory pathways such as AKT, HER3 and MET which enable tumor cells to escape the effects of conventional EGFR/HER2 inhibitors.1,2
Verwenden
Inhibitor of HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, respectively.
Verwenden
CUDC-101 is a potent multi-acting HDAC (histone deacetylase), EGFR (epidermal growth factor receptor), and HER2 ( human epidermal growth factor receptor 2) inhibitor for the treatment of cancer.
Allgemeine Beschreibung
A potent multitargeted inhibitor of histone deacetylase (HDAC) and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), with IC50 values of 4.4, 2.4, and 15.7 nM, respectively.

Displays potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.
target
EGFR
Einzelnachweise
1) Lai?et al. (2010),?CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potential anticancer activity; Cancer Res.,?70?3647 2) Cai?et al.?(2010), Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer; J. Med. Chem.,?53?2000

CUDC-101 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

1012054-59-9, CUDC-101 Verwandte Suche:

Send Inquriy